Clinuvel plans additional preclinical study of VLRX-L controlled-release peptide platform in Q1 2027

• Clinuvel updated on VLRX-L, a controlled-release liquid injectable peptide platform, following preclinical work already completed.
• One formulation showed a more favorable release profile in preclinical models, supporting continued development without disclosing detailed performance metrics.
• Work now shifts to refining the lead candidate, with a further preclinical study scheduled for early Q1 2027.
• Manufacturing scale-up is being scoped as the program targets flexible dosing for peptide drugs, initially focused on melanocortins.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clinuvel Pharmaceuticals Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-037231), on August 12, 2026, and is solely responsible for the information contained therein.